Carina Alvfors

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Mansoori, Sharmineh; Fryknäs, Mårten; Alvfors, Carina; Loskog, Angelica et al.

Part of Scientific Reports, 2021

• DOI for A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
• Download full text (pdf) of A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

Ekman, Simon; Harmenberg, Johan; Frödin, Jan-Erik; Bergström, Stefan et al.

Part of Acta Oncologica, p. 140-148, 2016

• DOI for A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Part of Investigational new drugs, p. 1232-1241, 2015

• DOI for First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

Ekman, Simon; Frödin, Jan-Erik; Harmenberg, Johan; Bergman, Antonina et al.

Part of Acta Oncologica, p. 441-447, 2011

• DOI for Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells.

Gullbo, Joachim; Arsenau, D; Grundmark, Birgitta; Alvfors, Carina et al.

Part of Anticancer Res, p. 4191, 2002

A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

Mansoori, Sharmineh; Fryknäs, Mårten; Alvfors, Carina; Loskog, Angelica et al.

Part of Scientific Reports, 2021

• DOI for A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
• Download full text (pdf) of A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer

A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

Ekman, Simon; Harmenberg, Johan; Frödin, Jan-Erik; Bergström, Stefan et al.

Part of Acta Oncologica, p. 140-148, 2016

• DOI for A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial.

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Åke; Ullen, Anders; Lisyanskaya, Alla; Orlov, Sergey et al.

Part of Investigational new drugs, p. 1232-1241, 2015

• DOI for First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

Ekman, Simon; Frödin, Jan-Erik; Harmenberg, Johan; Bergman, Antonina et al.

Part of Acta Oncologica, p. 441-447, 2011

• DOI for Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma

Cytotoxic activity of a new lipid formulation of doxorubicin in cell lines and primary tumor cells.

Gullbo, Joachim; Arsenau, D; Grundmark, Birgitta; Alvfors, Carina et al.

Part of Anticancer Res, p. 4191, 2002